SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose

Safety of COVID-19 vaccines in multiple sclerosis: A systematic review and meta-analysis

(2023) Maria-Ioanna Stefanou et al.   Multiple Sclerosis Journal

Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs

(2023) Rocco Capuano et al.   Multiple Sclerosis Journal

Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience

(2023) Andrea Bertozzi et al.   Multiple Sclerosis and Related Disorders

Frequency and Predictors of Relapses following SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis: Interim Results from a Longitudinal Observational Study

(2023) Niklas Frahm et al.   Journal of Clinical Medicine

Immunogenicity and Safety of a Third SARS-CoV-2 Vaccine Dose in Patients With Multiple Sclerosis and Weak Immune Response After COVID-19 Vaccination

(2022) Marton König et al.   JAMA Neurology

COVID‐19 vaccination hesitancy among people with chronic neurological disorders: A position paper

(2022) Martin Rakusa et al.   EUROPEAN JOURNAL OF NEUROLOGY

COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose

(2022) Sapir Dreyer-Alster et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod

(2022) Rocco Capuano et al.   Multiple Sclerosis and Related Disorders

Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis

(2022) Ethel Ciampi et al.   Multiple Sclerosis and Related Disorders

Case Report: Exacerbation of Relapses Following mRNA COVID-19 Vaccination in Multiple Sclerosis: A Case Series

(2022) Carlos Quintanilla-Bordás et al.   Frontiers in Neurology

Safety of Vaccines against SARS-CoV-2 among Polish Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies

(2022) Agata Czarnowska et al.   Vaccines

Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod

(2022) Rocco Capuano et al.   JOURNAL OF NEUROLOGY

To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection

(2022) Dominika Stastna et al.   Multiple Sclerosis and Related Disorders

Relapses after SARS-CoV-2 vaccination in patients with neuromyelitis optica spectrum disorder and multiple sclerosis

(2022) Lingyao Kong et al.   Multiple Sclerosis and Related Disorders

CNS inflammatory demyelinating events after COVID-19 vaccines: A case series and systematic review

(2022) Virginia Rinaldi et al.   Frontiers in Neurology

COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021

(2021) Anat Achiron et al.   Multiple Sclerosis Journal

SARS-CoV-2 vaccines: a triumph of science and collaboration

(2021) Jonathan L. Golob et al.   JCI Insight

Safety of the BNT162b2 COVID‐19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel

(2021) Itay Lotan et al.   EUROPEAN JOURNAL OF NEUROLOGY

mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis

(2021) Massimiliano Di Filippo et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

(2021) Yinon M. Bar-On et al.   NEW ENGLAND JOURNAL OF MEDICINE

COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: A follow up survey during the initial vaccine rollout in 2021

(2021) Dawn M. Ehde et al.   Multiple Sclerosis and Related Disorders

Severe Multiple Sclerosis Relapse After COVID-19 Vaccination: A Case Report

(2021) Giorgia T. Maniscalco et al.   Frontiers in Neurology

Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations

(2021) Verónica Cabreira et al.   Vaccines

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

(2021) Einav G. Levin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data

(2021) Samantha Epstein et al.   Multiple Sclerosis and Related Disorders

Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases

(2021) Riccardo Nistri et al.   Frontiers in Neurology

Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines

(2020) Hsin-I Shih et al.   Biomedical Journal

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vaccination in Multiple Sclerosis: Friend or Foe?

(2019) Tobias Zrzavy et al.   Frontiers in Immunology

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

(2018) Alan J Thompson et al.   LANCET NEUROLOGY

The spectrum of post-vaccination inflammatory CNS demyelinating syndromes

(2013) Dimitrios Karussis et al.   AUTOIMMUNITY REVIEWS

Immunizations and risk of multiple sclerosis: systematic review and meta-analysis

(2011) Mauricio F. Farez et al.   JOURNAL OF NEUROLOGY